R2R01
- Generic Name
- R2R01
To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)
Phase 2
Completed
- Conditions
- Worsening Heart Failure (WHF)Heart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- River 2 Renal Corp.
- Target Recruit Count
- 33
- Registration Number
- NCT06264310
- Locations
- 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸Piedmont Hospital Transplant, Atlanta, Georgia, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
Phase 2
Recruiting
- Conditions
- Hepatorenal SyndromeAcute Kidney Injury
- Interventions
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- River 2 Renal Corp.
- Target Recruit Count
- 95
- Registration Number
- NCT05875948
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Baylor Scott and White All Saints Medical Center, Fort Worth, Texas, United States
🇺🇸California Pacific Medical Center, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath